Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.

Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC.

Breast Cancer Res Treat. 2011 Jan;125(1):55-63. doi: 10.1007/s10549-010-0825-z. Epub 2010 Mar 12.

PMID:
20224928
2.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.

Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1131-40. doi: 10.1007/s00280-010-1455-1. Epub 2010 Sep 14.

PMID:
20838997
3.
4.

Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.

Chang H, Rha SY, Jeung HC, Jung JJ, Kim TS, Kwon HJ, Kim BS, Chung HC.

J Cancer Res Clin Oncol. 2010 Dec;136(12):1901-13. doi: 10.1007/s00432-010-0849-0. Epub 2010 Mar 9.

PMID:
20217129
5.

Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.

Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A.

Cancer Sci. 2010 Jun;101(6):1424-30. doi: 10.1111/j.1349-7006.2010.01559.x. Epub 2010 Mar 10.

6.

Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.

Angelucci A, Mari M, Millimaggi D, Giusti I, Carta G, Bologna M, Dolo V.

Gynecol Oncol. 2010 Dec;119(3):557-63. doi: 10.1016/j.ygyno.2010.07.036. Epub 2010 Sep 9.

PMID:
20825984
7.
8.

cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.

Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM.

Breast Cancer Res Treat. 2006 Mar;96(1):17-39. Epub 2005 Dec 2.

PMID:
16322897
9.

Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.

Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK.

Mol Cancer Ther. 2009 Jun;8(6):1596-605. doi: 10.1158/1535-7163.MCT-08-1004. Epub 2009 Jun 9.

10.

Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.

Dietrich CS 3rd, Greenberg VL, DeSimone CP, Modesitt SC, van Nagell JR, Craven R, Zimmer SG.

Gynecol Oncol. 2010 Jan;116(1):126-30. doi: 10.1016/j.ygyno.2009.09.039. Epub 2009 Oct 28.

PMID:
19875160
11.

Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.

Ong PS, Wang XQ, Lin HS, Chan SY, Ho PC.

Int J Oncol. 2012 May;40(5):1705-13. doi: 10.3892/ijo.2012.1354. Epub 2012 Feb 2.

PMID:
22328352
12.

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM.

Mol Cancer Ther. 2007 Jan;6(1):51-60. Epub 2007 Jan 11.

13.
14.

Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.

Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP.

Clin Cancer Res. 2006 Sep 15;12(18):5570-7.

15.

Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.

Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.

Cancer Chemother Pharmacol. 2006 Nov;58(5):640-53. Epub 2006 Mar 17.

PMID:
16544145
16.

Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.

Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV.

Cancer Chemother Pharmacol. 2005 Mar;55(3):277-85. Epub 2004 Nov 24.

PMID:
15565326
17.

In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?

Modesitt SC, Parsons SJ.

Gynecol Oncol. 2010 Nov;119(2):351-7. doi: 10.1016/j.ygyno.2010.06.030. Epub 2010 Jul 31.

PMID:
20673975
18.

Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells.

Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, Lee SM, Lee SJ, Park IC, Jin YW, An S.

Int J Mol Med. 2009 Jul;24(1):45-50.

PMID:
19513533
19.

1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.

Clinckspoor I, Verlinden L, Overbergh L, Korch C, Bouillon R, Mathieu C, Verstuyf A, Decallonne B.

J Steroid Biochem Mol Biol. 2011 Mar;124(1-2):1-9. doi: 10.1016/j.jsbmb.2010.12.008. Epub 2010 Dec 21.

PMID:
21182945
20.

In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.

Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR Jr, Zimmer SG, Modesitt SC.

Gynecol Oncol. 2007 Mar;104(3):596-601. Epub 2006 Oct 16.

PMID:
17049973

Supplemental Content

Support Center